Literature DB >> 1967930

HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.

S S Bacus1, J W Bacus, D J Slamon, M F Press.   

Abstract

This study was performed to evaluate the correlation between HER-2/neu gene expression and DNA ploidy patterns. Forty-five cases of breast-cancer were analyzed. Immunohistochemical staining of HER-2/neu protein on frozen sections was used to detect the HER-2/neu protein, and the Feulgen DNA staining method was used to assess DNA amounts in the same tumor cells. Positive HER-2/neu overexpression was evaluated visually, and quantitation of the HER-2/neu protein was measured by image analysis. Twenty-two of the 45 cases were visually scored to be positive for the overexpression of the HER-2/neu protein, and these cases also contained above 10% HER-2/neu protein compared with a standard control cell line. All 22 of these cases had near-tetraploid DNA content. In contrast, cells, derived from the 23 cases that did not overexpress the HER-2/neu protein, contained DNA amounts that ranged from euploid (diploid) to varying degrees of aneuploid. The results of this study indicated that tumors that overexpress the HER-2/neu protein have tetraploid or near-tetraploid DNA content. This pattern could relate to the biological behavior of these tumors.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1967930

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  13 in total

1.  Biological indices in the assessment of breast cancer.

Authors:  A S Leong; A K Lee
Journal:  Clin Mol Pathol       Date:  1995-10

2.  Induction of a cytoplasmic activator of DNA synthesis in lymphocytes is mediated through a membrane-associated protein kinase.

Authors:  M V Autieri; K L Fresa; F D Coffman; M E Katz; S Cohen
Journal:  Cell Regul       Date:  1990-12

3.  p53 mutations and expression in breast carcinoma in situ.

Authors:  J Lukas; N Niu; M F Press
Journal:  Am J Pathol       Date:  2000-01       Impact factor: 4.307

4.  Nuclear and flow cytometric characteristics associated with overexpression of the c-erbB-2 oncoprotein in breast carcinoma.

Authors:  D N Poller; M Galea; D Pearson; J Bell; W J Gullick; C W Elston; R W Blamey; I O Ellis
Journal:  Breast Cancer Res Treat       Date:  1991-12       Impact factor: 4.872

5.  Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors.

Authors:  C Charpin; B Devictor; P Bonnier; L Andrac; M N Lavaut; C Allasia; L Piana
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

6.  Maintenance of DNA content and erbB-2 alterations in intraductal and invasive phases of mammary cancer.

Authors:  J D Iglehart; B J Kerns; G Huper; J R Marks
Journal:  Breast Cancer Res Treat       Date:  1995-06       Impact factor: 4.872

7.  Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival.

Authors:  S Lei; H E Appert; B Nakata; D R Domenico; K Kim; J M Howard
Journal:  Int J Pancreatol       Date:  1995-02

8.  HER-2/neu oncogene expression and proliferation in breast cancers.

Authors:  S S Bacus; S G Ruby; D S Weinberg; D Chin; R Ortiz; J W Bacus
Journal:  Am J Pathol       Date:  1990-07       Impact factor: 4.307

9.  Development of a novel in vitro human tissue-based angiogenesis assay to evaluate the effect of antiangiogenic drugs.

Authors:  Eugene A Woltering; James M Lewis; P Johnstone Maxwell; Daniel J Frey; Yi-Zarn Wang; John Rothermel; Catherine T Anthony; Douglas A Balster; J Patrick O'Leary; Lynn H Harrison
Journal:  Ann Surg       Date:  2003-06       Impact factor: 12.969

10.  Immunohistochemical overexpression of C-erbB-2 in the prognosis of breast cancer.

Authors:  A Tsuchiya; N Katagata; I Kimijima; R Abe
Journal:  Surg Today       Date:  1993       Impact factor: 2.549

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.